Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic.

Slides:

Advertisements

Similar presentations

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Advertisements

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation Joseph H. Antin, Eva C. Guinan,

Comprehensive Genomic Profiling of Diagnostic Bone Marrow Specimens Identifies Mutational Profiles Predictive of Relapse in Patients with Acute Myeloid.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

The Role of Missing Killer Cell Immunoglobulin-Like Receptor Ligands in T Cell Replete Peripheral Blood Stem Cell Transplantation from HLA-Identical Siblings

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Sabina Kersting, Leo F. Verdonck

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Donor Selection for Killer Immunoglobulin-like Receptors B Haplotype of the Centromeric Motifs Can Improve the Outcome after HLA-Identical Sibling Hematopoietic.

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome Iskra Pusic,

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma Mark Korthals, Nina Sehnke, Ralf Kronenwett,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-

Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia Yu Wang,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

What is quality in a transplant program?

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Ibrahim.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study Luis F.

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Mammen Chandy Biology of Blood and Marrow Transplantation

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

Mary Eapen Biology of Blood and Marrow Transplantation

Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Presentation transcript:

Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation Gabriel N. Mannis, Thomas G. Martin, Lloyd E. Damon, Charalambos Andreadis, Rebecca L. Olin, Katherine A. Kong, Malek Faham, Jimmy Hwang, Weiyun Z. Ai, Karin M.L. Gaensler, Peter H. Sayre, Jeffrey L. Wolf, Aaron C. Logan Biology of Blood and Marrow Transplantation Volume 22, Issue 6, Pages 1030-1036 (June 2016) DOI: 10.1016/j.bbmt.2016.02.004 Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Relapse-free survival (RFS) and overall survival (OS) for patients who underwent autoHCT for ALL. (A) RFS and OS for the entire cohort, (B) RFS and OS for the Ph+ B-ALL cohort, (C) RFS and OS for the Ph− B-ALL cohort, and (D) RFS and OS for the T cell ALL cohort. Biology of Blood and Marrow Transplantation 2016 22, 1030-1036DOI: (10.1016/j.bbmt.2016.02.004) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Frequency of immunoglobulin and T cell receptor loci rearrangement detection in diagnostic samples. The number of leukemia-associated immunoreceptor locus rearrangements per patient is shown in (A). For each of the immunoreceptors tested, the frequency of clonotypes in diagnostic specimens is shown in (B). Biology of Blood and Marrow Transplantation 2016 22, 1030-1036DOI: (10.1016/j.bbmt.2016.02.004) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Effect of ex vivo purging using CD9, CD10, CD19, and CD20 monoclonal antibodies for B-ALL or CD2, CD3, CD4, CD5, and CD8 monoclonal antibodies for T-ALL on MRD in peripheral blood progenitor cell leukapheresis products of 3 patients with detectable MRD whose leukapheresis product underwent purging. Biology of Blood and Marrow Transplantation 2016 22, 1030-1036DOI: (10.1016/j.bbmt.2016.02.004) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Relapse-free survival (RFS) for the entire cohort, stratified by minimal residual disease (MRD) status. Using a threshold of detection of ≥10−6, MRD-negative patients experience significantly improved RFS, with the median not reached for MRD-negative patients and 6.5 months for MRD-positive patients (P = .0005). Biology of Blood and Marrow Transplantation 2016 22, 1030-1036DOI: (10.1016/j.bbmt.2016.02.004) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Supplementary Figure 1 Biology of Blood and Marrow Transplantation 2016 22, 1030-1036DOI: (10.1016/j.bbmt.2016.02.004) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions